期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 75, 期 8, 页码 919-930出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.11.062
关键词
antiaging therapy; biological age; biological age biomarkers; chronological age; vascular disease
资金
- MCNU
- ISCIII
- Pro CNIC Foundation
- Severo Ochoa Center of Excellence [SEV-2015-0505]
- Spanish Ministerio de Ciencia, Innovacion y Universidades (MCNU) [SAF201679490-R]
- Instituto de Salud Carlos III (ISCIII) [AC16/00091, AC17/00067, CB16/11/00405]
- European Regional Development Fund (ERDF/FEDER, Una manera de hacer Europa)
- Fundacio Marato TV3 [122/C/2015]
- MCNU [FJCI-2017-33299, BES-2017-079705]
- Ministerio de Educacion, Cultura y Deporte [FPU16/05027]
Aging is the main risk factor for vascular disease and ensuing cardiovascular and cerebrovascular events, the leading causes of death worldwide. In a progressively aging population, it is essential to develop early-life biomarkers that efficiently identify individuals who are at high risk of developing accelerated vascular damage, with the ultimate goat of improving primary prevention and reducing the health care and socioeconomic impact of age-related cardiovascular disease. Studies in experimental models and humans have identified 9 highly interconnected hallmark processes driving mammalian aging. However, strategies to extend health span and life span require understanding of interindividual differences in age-dependent functional decline, known as biological aging. This review summarizes the current knowledge on biological age biomarkers, factors influencing biological aging, and antiaging interventions, with a focus on vascular aspects of the aging process and its cardiovascular disease related manifestations. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据